Chart: Waxman Biosimilars Bill Adds Exclusivity, Tweaks Substitutability
You may also be interested in...
Biosimilar Interchangeability Does Not Create Substitution Under House Bills
While biosimilars legislation is seen as a means of lowering health care costs, interchangeability provisions in House bills creating a biosimilars approval pathway would not be enough to allow automatic substitution at the pharmacy level - the route to the highest savings
Follow-On Grudge Match: The Round One Scorecard In Waxman vs. Eshoo
Two versions of biosimilars legislation are now before the House, and the question is how much, if any, compromise will be needed to get a measure approved on that side of Capitol Hill
Biologics Exclusivity Will Be Less Then 10 Years, Teva’s Marth Vows
Any legislation creating a pathway for approving follow-on biologics will need to include a brand exclusivity period of less than 10 years, Teva North America CEO William Marth maintains